Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.verified

ARWR

Price:

$24.77

Market Cap:

$3.08B

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channe...[Read more]

Industry

Biotechnology

IPO Date

1993-12-16

Stock Exchange

NASDAQ

Ticker

ARWR

The PE Ratio as of May 2024 (TTM) for Arrowhead Pharmaceuticals, Inc. (ARWR) is -5.86

According to Arrowhead Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.86. This represents a change of -19.09% compared to the average of -7.24 of the last 4 quarters.

Arrowhead Pharmaceuticals, Inc. (ARWR) Historical PE Ratio (quarterly & annually)

How has ARWR PE Ratio performed in the past?

The mean historical PE Ratio of Arrowhead Pharmaceuticals, Inc. over the last ten years is -15.17. The current -5.86 PE Ratio has changed 3.76% with respect to the historical average. Over the past ten years (40 quarters), ARWR's PE Ratio was at its highest in in the September 2019 quarter at 57.39. The PE Ratio was at its lowest in in the December 2019 quarter at -575.83.

Quarterly (TTM)
Annual

Average

-15.17

Median

-12.89

Minimum

-51.29

Maximum

38.91

Arrowhead Pharmaceuticals, Inc. (ARWR) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Arrowhead Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 220.29%

Maximum Annual PE Ratio = 38.91

Minimum Annual Increase = -231.87%

Minimum Annual PE Ratio = -51.29

Quarterly (TTM)
Annual
YearPE RatioChange
2023-13.97-29.22%
2022-19.74-57.07%
2021-45.98-10.35%
2020-51.29-231.83%
201938.91-231.87%
2018-29.51220.29%
2017-9.2167.96%
2016-5.4952.64%
2015-3.59-69.59%
2014-11.82169.96%

Arrowhead Pharmaceuticals, Inc. (ARWR) Average PE Ratio

How has ARWR PE Ratio performed in the past?

The current PE Ratio of Arrowhead Pharmaceuticals, Inc. (ARWR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-26.57

5-year avg

-18.42

10-year avg

-15.17

Arrowhead Pharmaceuticals, Inc. (ARWR) PE Ratio vs. Peers

How is ARWR’s PE Ratio compared to its peers?

Arrowhead Pharmaceuticals, Inc.’s PE Ratio is greater than Wave Life Sciences Ltd. (-13.12), less than CytomX Therapeutics, Inc. (9.38), less than Assembly Biosciences, Inc. (-1.55), less than Neoleukin Therapeutics, Inc. (-0.98), less than BioMarin Pharmaceutical Inc. (71.30), less than Incyte Corporation (17.20), greater than Ionis Pharmaceuticals, Inc. (-14.14), greater than Apellis Pharmaceuticals, Inc. (-12.17), less than ProQR Therapeutics N.V. (-5.44), less than Annexon, Inc. (-4.40), greater than Day One Biopharmaceuticals, Inc. (-6.71), less than Terns Pharmaceuticals, Inc. (-4.82), less than Mirati Therapeutics, Inc. (-5.32), less than Amylyx Pharmaceuticals, Inc. (-1.75), greater than IVERIC bio, Inc. (-33.43), greater than Blueprint Medicines Corporation (-22.42), greater than Karuna Therapeutics, Inc. (-29.52),

Build a custom stock screener for Arrowhead Pharmaceuticals, Inc. (ARWR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arrowhead Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Arrowhead Pharmaceuticals, Inc. (ARWR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Arrowhead Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Arrowhead Pharmaceuticals, Inc.'s PE Ratio?

How is the PE Ratio calculated for Arrowhead Pharmaceuticals, Inc. (ARWR)?

What is the highest PE Ratio for Arrowhead Pharmaceuticals, Inc. (ARWR)?

What is the 3-year average PE Ratio for Arrowhead Pharmaceuticals, Inc. (ARWR)?

What is the 5-year average PE Ratio for Arrowhead Pharmaceuticals, Inc. (ARWR)?

How does the current PE Ratio for Arrowhead Pharmaceuticals, Inc. (ARWR) compare to its historical average?